



## ASX Announcement

26 May 2026

# 2026 Annual General Meeting Results

**Melbourne, Australia, 26 May 2026** – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001 (Cth)*, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

### For enquiries, please contact

Naomi Lawrie  
Company Secretary  
+61 1300 384 692

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

### About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's lead asset is a proprietary cannabidiol ("CBD") TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia.

See more here - [avecho.com.au](https://avecho.com.au)

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details                                                                       |                    | Instructions given to validly appointed proxies<br>(as at proxy close) |                     |                       |            | Number of votes cast on the poll<br>(where applicable) |                     |            | Resolution<br>Result     |
|------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------|---------------------|-----------------------|------------|--------------------------------------------------------|---------------------|------------|--------------------------|
| Resolution                                                                               | Resolution<br>Type | For                                                                    | Against             | Proxy's<br>Discretion | Abstain    | For                                                    | Against             | Abstain*   | Carried /<br>Not Carried |
| 1 Adoption of Remuneration Report                                                        | Ordinary           | 1,187,473,648<br>96.74%                                                | 26,869,297<br>2.19% | 13,179,918<br>1.07%   | 3,513,727  | 1,240,030,875<br>97.88%                                | 26,869,297<br>2.12% | 3,513,727  | Carried                  |
| 2 Re-Election of Mr Matthew Patrick McNamara as a Director of the Company                | Ordinary           | This resolution was withdrawn                                          |                     |                       |            | This resolution was withdrawn                          |                     |            | Withdrawn                |
| 3 Renewal of Avecho Biotechnology Limited Equity Incentive Plan                          | Ordinary           | 1,188,484,836<br>96.80%                                                | 26,096,665<br>2.13% | 13,178,807<br>1.07%   | 19,793,789 | 1,240,840,952<br>97.92%                                | 26,296,665<br>2.08% | 19,793,789 | Carried                  |
| 4 Ratification of prior Issue of 182,653,633 Shares under Placement                      | Ordinary           | 1,103,464,777<br>96.75%                                                | 23,726,771<br>2.08% | 13,363,807<br>1.17%   | 3,832,075  | 1,179,095,558<br>98.02%                                | 23,803,771<br>1.98% | 3,832,075  | Carried                  |
| 5 Ratification of prior Issue of 20,000,000 Options to the Lead Manager (or its nominee) | Ordinary           | 1,139,016,466<br>95.77%                                                | 36,970,098<br>3.11% | 13,363,807<br>1.12%   | 64,037,059 | 1,214,524,247<br>97.03%                                | 37,170,098<br>2.97% | 64,037,059 | Carried                  |
| 6 Approval of 10% Placement Facility                                                     | Special            | 1,211,907,522<br>97.03%                                                | 23,746,128<br>1.90% | 13,363,807<br>1.07%   | 4,369,973  | 1,287,415,303<br>98.17%                                | 23,946,128<br>1.83% | 4,369,973  | Carried                  |

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

| Resolution                                                                | Reasons(s) for not putting resolution to the meeting |
|---------------------------------------------------------------------------|------------------------------------------------------|
| 2 Re-Election of Mr Matthew Patrick McNamara as a Director of the Company | Refer to ASX Announcement dated 25 May 2026          |